DexCom (DXCM) Competitors $84.13 -0.65 (-0.77%) Closing price 04:00 PM EasternExtended Trading$84.19 +0.06 (+0.07%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DXCM vs. HQY, PODD, ABT, AMN, ITGR, MDT, BDX, EW, IDXX, and RMDShould you be buying DexCom stock or one of its competitors? The main competitors of DexCom include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), Integer (ITGR), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and ResMed (RMD). These companies are all part of the "medical" sector. DexCom vs. Its Competitors HealthEquity Insulet Abbott Laboratories AMN Healthcare Services Integer Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories ResMed HealthEquity (NASDAQ:HQY) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Which has higher earnings and valuation, HQY or DXCM? DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHealthEquity$1.20B7.04$96.70M$1.3771.29DexCom$4.03B8.18$576.20M$1.3462.78 Does the media refer more to HQY or DXCM? In the previous week, DexCom had 12 more articles in the media than HealthEquity. MarketBeat recorded 19 mentions for DexCom and 7 mentions for HealthEquity. DexCom's average media sentiment score of 1.44 beat HealthEquity's score of 1.05 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in HQY or DXCM? 99.6% of HealthEquity shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.5% of HealthEquity shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is HQY or DXCM more profitable? DexCom has a net margin of 12.90% compared to HealthEquity's net margin of 9.80%. DexCom's return on equity of 30.05% beat HealthEquity's return on equity.Company Net Margins Return on Equity Return on Assets HealthEquity9.80% 11.01% 6.77% DexCom 12.90%30.05%10.00% Do analysts prefer HQY or DXCM? HealthEquity presently has a consensus price target of $118.55, indicating a potential upside of 21.37%. DexCom has a consensus price target of $99.60, indicating a potential upside of 18.39%. Given HealthEquity's stronger consensus rating and higher probable upside, research analysts clearly believe HealthEquity is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HealthEquity 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00DexCom 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.91 Which has more volatility and risk, HQY or DXCM? HealthEquity has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. SummaryDexCom beats HealthEquity on 11 of the 17 factors compared between the two stocks. Get DexCom News Delivered to You Automatically Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXCM vs. The Competition Export to ExcelMetricDexComMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.24B$6.58B$5.52B$9.32BDividend YieldN/A1.30%4.25%4.05%P/E Ratio62.7825.4928.1519.68Price / Sales8.1867.67438.33100.29Price / Cash37.7220.0535.5357.53Price / Book15.644.668.235.67Net Income$576.20M$174.76M$3.23B$257.51M7 Day Performance-0.87%-1.13%-0.01%0.52%1 Month Performance1.36%1.21%5.61%8.84%1 Year Performance-27.51%2.34%26.52%14.18% DexCom Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXCMDexCom4.7821 of 5 stars$84.13-0.8%$99.60+18.4%-25.0%$33.24B$4.03B62.7810,300Positive NewsAnalyst ForecastHQYHealthEquity3.0088 of 5 stars$101.45-0.7%$118.09+16.4%+24.8%$8.77B$1.20B74.053,120Positive NewsPODDInsulet4.5696 of 5 stars$299.18-0.6%$321.00+7.3%+45.8%$21.05B$2.20B53.813,900Positive NewsAnalyst RevisionABTAbbott Laboratories4.9439 of 5 stars$133.08-1.0%$142.61+7.2%+27.6%$231.54B$41.95B17.26114,000Trending NewsUpcoming EarningsAnalyst ForecastAMNAMN Healthcare Services4.2438 of 5 stars$21.25-3.1%$32.08+51.0%-61.5%$813.45M$2.98B-4.912,968ITGRInteger3.1727 of 5 stars$116.26-3.9%$145.00+24.7%-2.0%$4.06B$1.72B55.1011,000News CoveragePositive NewsMDTMedtronic4.4623 of 5 stars$87.58-0.9%$97.87+11.7%+15.7%$112.32B$33.54B24.1995,000Positive NewsAnalyst ForecastAnalyst RevisionBDXBecton, Dickinson and Company4.8166 of 5 stars$172.51-2.1%$219.22+27.1%-21.1%$49.44B$20.18B32.9274,000Positive NewsAnalyst RevisionEWEdwards Lifesciences4.3568 of 5 stars$76.63-0.2%$80.20+4.7%-14.1%$44.95B$5.44B10.9515,800Positive NewsUpcoming EarningsAnalyst ForecastIDXXIDEXX Laboratories3.6435 of 5 stars$543.82-0.6%$558.11+2.6%+9.1%$43.73B$3.90B50.2611,000Positive NewsRMDResMed4.4255 of 5 stars$255.95-0.4%$259.33+1.3%+22.7%$37.53B$4.69B28.739,980News CoveragePositive NewsAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies HealthEquity Competitors Insulet Competitors Abbott Laboratories Competitors AMN Healthcare Services Competitors Integer Competitors Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors IDEXX Laboratories Competitors ResMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DXCM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
